DrugPatentWatch Database Preview
Details for Patent: 8,231,885
Which drugs does patent 8,231,885 protect, and when does it expire?
Patent 8,231,885 protects MIRVASO and is included in one NDA.
This patent has sixty-four patent family members in twenty-four countries.
This patent has sixty-four patent family members in twenty-four countries.
Summary for Patent: 8,231,885
| Title: | Compounds, formulations, and methods for ameliorating telangiectasis |
| Abstract: | Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours. |
| Inventor(s): | DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ) |
| Assignee: | Galderma Laboratories Inc. (Fort Worth, TX) |
| Application Number: | 12/544,663 |
|
Patent Claim Types: see list of patent claims | Composition; Delivery; Formulation; |
Drugs Protected by US Patent 8,231,885
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,231,885
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,859,551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ➤ Sign Up |
| 8,557,817 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ➤ Sign Up |
| 8,410,102 | Methods and compositions for treating or preventing erythema | ➤ Sign Up |
| 8,426,410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 8,231,885
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 530185 | ➤ Sign Up | |||
| Australia | 2004242967 | ➤ Sign Up | |||
| Australia | 2005247467 | ➤ Sign Up | |||
| Australia | 2011231543 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
